Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linan Zhu

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Leukemia & Lymphoma|January 19, 2023
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphomaMeng Lin, Xiaolong Wu, Lei Zhang, et al.
Frontiers in Nutrition|October 24, 2022
The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in ChinaJingjing Ge, Yaxin Lei, Qing Wen, et al.
Cancer|January 4, 2026
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphomaWanyue Zhao, Ling Li, Xiaorui Fu, et al.
Frontiers in Oncology|July 5, 2021
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment FailureJunxia Hu, Xin Wang, Fei Chen, et al.
Cancer Biology & Medicine|October 11, 2021
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trialJingjing Wu, Fenghua Gao, Wenhua Wang, et al.
Therapeutic Advances in Medical Oncology|March 9, 2026
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysisXudong Zhang, Wanyue Zhao, Wenhua Wang, et al.
JAMA Oncology|June 16, 2022
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical TrialXinhua Wang, Lei Zhang, Xiangli Liu, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Leukemia & Lymphoma|January 19, 2023
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphomaMeng Lin, Xiaolong Wu, Lei Zhang, et al.
Frontiers in Nutrition|October 24, 2022
The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in ChinaJingjing Ge, Yaxin Lei, Qing Wen, et al.
Cancer|January 4, 2026
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphomaWanyue Zhao, Ling Li, Xiaorui Fu, et al.
Frontiers in Oncology|July 5, 2021
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment FailureJunxia Hu, Xin Wang, Fei Chen, et al.
Cancer Biology & Medicine|October 11, 2021
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trialJingjing Wu, Fenghua Gao, Wenhua Wang, et al.
Therapeutic Advances in Medical Oncology|March 9, 2026
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysisXudong Zhang, Wanyue Zhao, Wenhua Wang, et al.
JAMA Oncology|June 16, 2022
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical TrialXinhua Wang, Lei Zhang, Xiangli Liu, et al.
Pageof 3